NO | مەھسۇلاتلار | Cas no | ئاچقۇچلۇق سۈپەت كۆرسەتكۈچى | |||
Purity | Max. effurity | ئومۇمىي ھەل قىلىش پۇرسىتى | نەملىك | |||
1 | FMOC-β-ALA-ALA-AHA | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
2 | Fmoc-d-Ala-D-Ala-Ala-AH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
3 | Fmoc-β-ALA-D-ALA-ALA-AH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
4 | Fmoc-arg (PBF) -arg (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
5 | FMOC-β-ALA-ALG (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
6 | Fmoc-d-arg (PBF) -D-ARG (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
7 | FMOC-β-ALA-D-D-ARG (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
8 | FMOC-HOMOARG (PBF) ---وزگ (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
9 | FMOC-β-ALA-ALAARG (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
10 | Fmoc-asn (TRT) -ھەن (TRA) -ھە | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
11 | FMOC-β-Ala-ASN (TRT) -ھە | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
12 | FMOC-asp (OTBU) -ASP (OTBU) -ھە | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
13 | FMOC-β-ALA-ALA-ASP (OTBU) -ھە | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
14 | FMoc-cys (TRT) -و (TRT )-- | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
15 | FMOC-β-ALA-CYS (TRT) -ھە | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
16 | FMOC-CYS (ACM) - | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
17 | FMOC-β-ALA-CYS (ACM) -ھە | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
18 | Fmoc-gln (TRT) -Gln (TRT) -ھە | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
19 | FMOC-β-ALA-GLN (TRT) -ھە | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
20 | FMOC-Glu (OTBU)-تىزىملىك (OTBU) -ھە | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
21 | FMOC-β-ALA-GLU (OTBU) -oh.h2o | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
22 | Fmoc-β-ALA-Gly-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
23 | Fmoc-his (tranclin) -his (TRT) -ھە | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
24 | FMOC-β-ALA-ALA (TRT )- | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
25 | Fmoc-ile-ile-ile-ih | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
26 | FMOC-β-ALA-ILE-IY-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
27 | Fmoc-leu-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
28 | Fmoc-β-ALA-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
29 | Fmoc-d-leu-d-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
30 | Fmoc-β-ALA-D-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
31 | FMOC-Lys (BOC) -lys (boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
32 | FMOC-β-ALA-LYS (BOC) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
33 | FMOC-Lys (alcloc) -lys -ly (alcloc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
34 | Fmoc-β-ALA-LYS (alcloc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
35 | Fmoc-mets nown-hange-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
36 | FMOC-β-ALA-ALA-ALA-AH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
37 | FMOC-orn (boc)--ور (بوكو) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
38 | FMOC-β-ALA-orn (Boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
39 | Fmoc-phe-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
40 | Fmoc-β-ALA-PHE-AH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
41 | Fmoc-d-phe-d-phe-a-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
42 | Fmoc-β-ALA-D-D-Phe-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
43 | Fmoc-pro-pro-ah | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
44 | Fmoc-β-ALA-ALA-AL-AH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
45 | FMOC-SEAR (TBU) --TBU (TBU )-h | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
46 | FMOC-β-ALA-ALA-ALA (TBU )-h | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
47 | FMOC-SE (TRA) --- " | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
48 | FMOC-β Ala-Ala (TRT) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
49 | Fmoc-thr (tbu)---hr (TBU)--oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
50 | FMOC-β-ALA-THR (TBU) -ھە | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
51 | FMOC-TRP (BOC) -RP (BOC )-h | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
52 | Fmoc-β-ALA-TRP (BOC) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
53 | FMOC-D-TRP (BOC) -D-Tr-Trp (boc) -o | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
54 | Fmoc-β-ALA-D-D-TRP (BOC) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
55 | FMOC-TYR (TBU)---قۇنە (TBU) -ھە | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
56 | FMOC-β-ALA-TYR (TBU) -ھە | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
57 | FMOC-D-Tyr (ET) (ET) -D-ALR (ETS) -ھە | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
58 | FMOC-β-ALA-D-D-Tyr (ET) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
59 | FMOC-TYR (ME)----مەن (مەن) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
60 | FMOC-β-ALA-TYR (ME) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
61 | Fmoc-val-val-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
62 | Fmoc-β-ALA-ALA-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
63 | Fmoc-d-cit-d-cit-fit-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
64 | FMOC-β-ALA-D-cit-fit-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
65 | Fmoc-β-ALA-DAB-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
66 | FMOC- ((3- (2-نافېل)-ALA) 2-ALA | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
67 | Fmoc-β-ALA-3- (2-nohthyl)-ALA-ALA-AHA | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
68 | Fmoc- ((3- (3- PYRIDINYL)-ALA (AD-ALA) 2-ئاھ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
69 | Fmoc-β-ALA-3- (3-PYRIDINYL)-ALA-ALA-AH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
70 | Fmoc- (4-خلورو-D-Phe) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
71 | Fmoc-β-ALA-4-CHLOO-D-D-Phe-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
72 | Fmoc- (D-4APH (TBucbm)) 2-ئاھ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
73 | FMOC-β-ALA-4A-4APH (TBucbm) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
74 | FMOC-APH (L-HOM) -APH (L-HOR) -ھە | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
75 | FMOC-β-ALA-APH (L-HOR)--h | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
76 | FMOC-Lys (IPR, BOC) - - (IPR, BOC) -o.h | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
77 | FMOC-β-ALA-LYS (IPR, BOC) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
78 | Fmoc-β-ALA-AEEA-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
79 | Fmoc-aib-aib-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
80 | Fmoc-β-ALA-AIB-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
81 | Fmoc-arg-oh | 91000-69-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
82 | H-arg (pbf) -oh | 200115-86-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
83 | Fmoc-d-arg-oh | 130752-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
84 | Hd-arg (pbf) -oh | 20016-81-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
85 | Fmoc-homoarg-oh.hcl | 20817-4-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
86 | H-HOMOARG (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
87 | Fmoc-d-homoarg-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
88 | HD-HOMOARG (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
89 | Fmoc-asn-oh | 71989-16-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
90 | H-asn (TRT )-h | 132388-58-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
91 | Fmoc-asp-oh | 119062--------------- | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
92 | H-asp (Otbu) -ھە | 3057-74-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
93 | Fmoc-cys-cys-oh | 135248-89-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
94 | H-CYS (TRT) -ھە | 2799/7/7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
95 | H-CYS (ACM) -oh.hcl | 28798-28-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
96 | Fmoc-gln-oh | 71989-20-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
97 | H-gln (TRT) -ھە-h | 102747-84-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
98 | Fmoc-glu-oh | 121344-82-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
99 | H-glu (OTBU) - -oh.h2o | 2419-56-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
100 | Fmoc-his-ha | 116611-64--4-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
101 | H-hera (TRT )-h | 35146-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
102 | Boc-his-feh | 1779-52-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
103 | Fmoc-lys-oh | 105047-45-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
104 | H-lys (boc) -oh | 2418-95-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
105 | H-lys (alclo) -oh | 6298/9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
106 | Fmoc-orn-ohn.hl | 201046-57-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
107 | H-orn (boc) -oh | 13650-49-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
108 | Fmoc-ser-oh | 73724-45-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
109 | H-SEAR (TBU)--oh | 1882-58-7-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
110 | H-ser (TRA) -ھە | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
111 | Fmoc-thr-oh.h2o | 73731-37-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
112 | H-thr (tbu)--h | 4378-13-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
113 | Fmoc-trp-oh | 35737-15-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
114 | H-trp (boc) -oh | 146645-63-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
115 | Fmoc-d-trp-oh | 86123-11-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
116 | HD-Trp (boc) -oh | 2012-يىلى 20-11-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
117 | FMOC-TYR-OH | 92954-90-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
118 | H-tyr (tbu)--h | 1882-59-29-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
119 | Fmoc-d-tyr-oh | 11283-29-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
120 | Hd-tyr (et) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
121 | H-tyr (me)---hi.hcl | 67423-44-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
122 | FMOC-D-4APH (CBM) -ھە | 324017-22-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
123 | HD-4APH (TBucbm) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
124 | Fmoc-lys (ipr) -ھە | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
125 | H-lys (ipr, boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
تۆلەم
گېنتوگكىس ئېسىل مەھسۇلاتلارنى تەمىنلىگەن بولسا, يېتەرلىك ۋاقىتتا لازىم بولغان ۋاقىت ئىچىدە خېرىدارنىڭ سۈپىتى يۇقىرى بولغان بولسا, تۆلەم تەرتىپىگە يوللاشقا تاپشۇرۇپ بېرىش ۋە باھالاش تەييارلاش ئۈچۈن زۆرۈر ئاندىيا ۋە باھالاشلار بىلەن تەمىنلەيمىز.
ئىشلەپچىقىرىش
دورا مەھسۇلاتلىرىنىڭ پايچېكى راكېتالغا يېتىپ كەلگەنلىكى, خىمىيىلىك مەھسۇلاتلارنىڭ مەخپىيلىشىى 100ToNing + دەرىجىسى Kenter غا يېتىدۇ, ئىقتىدارى ياخشى سەپكە سەپلەنگەن.
تەتقىقات ۋە تەرەققىيات
ھەر يىلى R & D گۇرۇپپىسىنىڭ ئوخشىمىغان يېڭى مەھسۇلاتلىرىنى تەرەققىي قىلدۇرۇش پىلانىنىڭ پىلانى ئورنىتىلغان, نىشان توپلانغان ۋاقىتتا, كوماندىدىكى ھەر بىر ئەزا KpPian ۋە رىغبەتلەندۈرۈش سىياسىتىدە چىڭ تۇرۇشى كېرەك.